Kazia Therapeutics Annual Report 2021

January 2021 GBM AGILE commences recruitment to the paxalisib arm, marking formal initiation of the international registration study for the drug. March 2021 Kazia partners Cantrixil legacy asset to Oasmia Pharmaceutical of Sweden for US$ 4 million upfront, up to US$ 42 million in contingent milestones, and double-digit royalties. March 2021 Kazia partners paxalisib for Greater China to Simcere Pharmaceutical for US$ 11 million upfront, up to US$ 281 million in contingent milestones, and tiered mid-teen royalties. April 2021 Kazia in-licenses EVT801, a selective small- molecule inhibitor of VEGFR3, from Evotec SE of Germany for € 1 million upfront, approximately € 300 million in contingent milestones, and single-digit royalties. June 2021 Kazia enters into a partnership with Cornell University to explore paxalisib in combination with a ketogenic diet in a phase II trial for glioblastoma. June 2021 Key manufacturing patents granted for paxalisib, with potential to protect manufacturing process to 2036. Kazia Therapeutics Limited Annual Report 2021 9 2021 AT A GLANCE CHAIRMAN’S LETTER CEO’S REPORT KEY MILESTONES PIPELINE REVIEW PARTNER FOR SUCCESS WORK WITH THE BEST #2 IN THE KAZIA STORY FINANCIAL REPORTS